Internet for Pharmaceutical and Biotech Communities
| Newsletter | Post Jobs | Advertising |
 
 
 

  

Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 
   



 

Title:  Modified HIV-1gag p17 peptide and immunogenic composition
United States Patent: 
7,009,037
Issued: 
March 7, 2006
Inventors: 
Sorensen; Birger (Skien, NO)
Assignee:
 Bionor Immuno AS (Gulset, NO)
Appl. No.: 
129331
Filed: 
September 3, 2001
PCT Filed: 
September 3, 2001
PCT NO: 
PCT/NO01/00362
371 Date: 
June 11, 2002
102(e) Date: 
June 11, 2002
PCT PUB.NO.: 
WO02/20554
PCT PUB. Date: 
March 14, 2002


 

Training Courses --Pharm/Biotech/etc.


Abstract

The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p17 and p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.

DESCRIPTION OF THE INVENTION

The peptides according to the invention are originating from the four different conserved areas of the HIV-1 gag protein p17 and p24 which are described above, having the properties of maintaining the uniqueness of the HIV-1-epitope. Further the new peptides according to the invention possess no recognized cytotoxic T lymphocyte (CTL) antagonistic effect and shall have at least one potential CTL epitope.

The peptides, according to the invention, which have met the above criteria are selected from the following groups;

Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 (SEQ ID NO: 1)  
 
Gln Leu Gln Xaa11 Xaa12 Xaa13 Xaa14
 
Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21

wherein the amino acids of the chain could have the following meanings;

  • Xaa in position 1 of the peptide derivate is His, Lys or Arg,
  • Xaa in position 2 is Ile, Leu, Val or Met,
  • Xaa in position 3 is Ile or Val,
  • Xaa in position 4 is Trp or Tyr,
  • Xaa in position 5 is Ala or Leu,
  • Xaa in position 6 is Ser, Thr, Arg or Asn,
  • Xaa in position 7 is Arg or Ser,
  • Xaa in position 11 is Arg, Lys, Gly or Asn,
  • Xaa in position 12 is Phe, Ser or Tyr
  • Xaa in position 13 is Ala, Thr or Ser
  • Xaa in position 14 is Val, Leu, Ile or Cys,
  • Xaa in position 15 is Asn, Asp or Ser,
  • Xaa in position 16 is Pro, Arg or Ser,
  • Xaa in position 17 is Gly, Ser, Ala, Asp or Asn
  • Xaa in position 18 is Leu or Phe,
  • Xaa in position 19 is Leu or Met,
  • Xaa in position 20 is Glu, Gly, Asp or Ile,
  • Xaa in position 21 is Thr, Ser or Ala
    the peptide comprises at least six consecutive amino acids of the sequence of SEQ ID NO: 1,
    Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 (SEQ ID NO: 4)  
     
    Gly Xaa9 Leu Val —Z—Tyr Xaa13 Xaa14
     
    Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20
     
    Xaa21 Ala Xaa23 Xaa24 Xaa25 Xaa26


    wherein the amino acids of the chain have the following meaning;

  • Xaa in position 1 is Pro, Tyr or Phe
  • Xaa in position 2 is Ile, Val or Leu,
  • Xaa in position 3 is Ile, Ala, Val, Met or Leu
  • Xaa in position 4 is Gln, Ser, Thr or Val
  • Xaa in position 5 is Asn, Asp or Thr
  • Xaa in position 6 is Ile, Ala, Leu or Met
  • Xaa in position 7 is Gln, Glu Lys or Gly
  • Xaa in position 9 is Gin or Ile
  • Xaa in position 13 is omitted
  • Xaa in position 14 is Ala, Ser, Asn, Val or Pro
  • Xaa in position 15 is Ile, Leu, Met or Val,
  • Xaa in position 16 is Ser or Thr
  • Xaa in position 17 is Pro or Ala,
  • Xaa in position 18 is Arg or Lys,
  • Xaa in position 19 is Thr or Ser
  • Xaa in position 20 is Leu or Ser
  • Xaa in position 21 is Asn, Phe or Val,
  • Xaa in position 23 is Trp, Tyr, Gly or none
  • Xaa in position 24 is Val, Leu, Gly or none
  • Xaa in position 25 is Lys, Arg, Gly or none
  • Xaa in position 26 is Val, Ala, Cys, Gly or none
    wherein the sequence of SEQ ID NO: 4 comprises at least six consecutive amino acids and —Z— is optional and have the meaning PEG, modified PEG and/or [Gly]n, wherein n=1, 2 or 3,
    Xaa1 Ala Xaa3 Xaa4 Xaa5 Ala Xaa7 (SEQ ID NO: 9)  
     
    Xaa8 Xaa9 Leu Leu Xaa12 Xaa13
     
    Xaa14—Z—Xaa15 Xaa16 His Gln Xaa19 Ala
     
    Xaa21 Xaa22


    wherein Xaa in position 1 is Tyr, Trp, Phe or Gly

  • Xaa in position 3 is Thr, Ala, Val, Ile or Leu
  • Xaa in position 4 is Pro or Ser
  • Xaa in position 5 is Gin, His, Gly, Thr, Ser or Tyr
  • Xaa in position 7 is Leu, Ile or Val
  • Xaa in position 8 is Asn or Tyr
  • Xaa in position 9 is Thr, Met, Leu or Ala
  • Xaa in position 12 is Ser, Thr or Asn
  • Xaa in position 13 is Thr, Ile, Val or Ala
  • Xaa in position 14 is Val or Ile
  • Xaa in position 15 is Gly or none
  • Xaa in position 16 is Gly or none
  • Xaa in position 19 is Ala or Gly
  • Xaa in position 21 is Met, Leu, Cys or none
  • Xaa in position 22 is Gln, Glu, His, Gly or none
    wherein the sequence of SEQ ID NO: 9 consists of at least six consecutive amino acids and the linker —Z— is optional and have the meaning PEG, modified PEG and/or [Gly]n, wherein n=1, 2 or 3,
    Xaa1 Xaa2 Ala Leu Ala Gly Xaa7 (SEQ ID NO: 15)  
     
    Xaa8 Xaa9 Leu Xaa11 Xaa12 Xaa13
     
    Xaa14 Xaa15 Xaa16 Xaa17 Xaa18 Xaa19
     
    Xaa20 Xaa21


    wherein the Xaa in position 1 is Trp or Tyr

  • Xaa in position 2 is Ser or Ala
  • Xaa in position 7 is Thr, Ala or Ser
  • Xaa in position 8 is Ser or Thr
  • Xaa in position 9 is Ser or Thr
  • Xaa in position 11 is Leu, Pro, Val or Gln
  • Xaa in position 12 is Gln, Ala or His
  • Xaa in position 13 is Glu or Gly
  • Xaa in position 14 is Gln or His
  • Xaa in position 15 is Ile, Leu, Val or Met
  • Xaa in position 16 is Gly, Ala, Gln, Thr, Asn, Arg, His or Ile
  • Xaa in position 17 is Trp or Tyr
  • Xaa in position 18 is Thr, Met, Leu or Ile
  • Xaa in position 19 is Thr or Ser
  • Xaa in position 20 is Cys, Gly or none
  • Xaa in position 21 is Gly or none
    wherein the sequence of SEQ ID NO: 15 consists of at least six consecutive amino acids,
    the terminal ends of the sequences may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof,
    two or more of the Cys residues may form part of an interchain disulphide binding, a —S—(CH2)p—S— or a —(CH2)p-bridge wherein p=1-8, optionally intervened by one or more hetero atoms such as O, N or S and/or the said peptide sequences are immobilized to a solid support.

    The new peptide sequences have the potential to serve as a good antigen wherein the antigen comprises at least one peptide selected from the group of sequences of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 9 or SEQ ID NO: 15. The antigenicity may be adapted through adjusting the ratio or concentration of different peptides or size of the peptides by for instance dimerization or polymerization and/or immobilization to a solid phase. The antigen comprises two or more polypeptide sequences, according to the invention, which are either linked by a bridge for instance a disulphide bridge between the Cys residues of the chains or bridges like C1-C8 alkylen possibly intervened by one or more heteroatoms like O, S, or N or preferably they are unlinked. The chains may be immobilized to a solid phase in monomeric, dimeric or oligomeric forms. Further amino acids may be added to the ends in order to achieve an <<arm>> to facilitate immobilization.

    PEG is polyethylene glycol (HO(CH2CH2O)mH and can be part of the linker —Z—, optionally PEG is modified by a dicarboxylic acid (HO(CH2CH2O)mCO(CH2)oCOOH) or a terminal carboxylic group (HO(CH2CH2O)m-1CH2COOH) where m=1-10 and o=2-6, prior to linking.

    The linker —Z— can either consist of PEG, modified PEG, or a combination thereof and/or one or more Gly residues combined. Alternatively the linker —Z— can consist of a Gly-bridge [Gly]n where n=1, 2 or 3.

    All amino acids in the peptides of the invention can be in both D- or L-form, although the naturally occurring L-form is preferred.

    The C- and N-terminal ends of the peptide sequences could deviate from the natural sequences by modification of the terminal NH2-group and/or COOH-group, they may for instance be acylated, acetylated, amidated or modified to provide a binding site for a carrier or another molecule.

    The peptides according to the invention are consisting of at least 6 amino acids, preferably between 10 and 30 amino acids. They are covering all natural variation of amino acids in the identified positions.

    The polypeptide antigen according to the invention is either in a free or in a carrier-bound form. The carrier or solid phase to which the peptide is optionally bound can be selected from a vide variety of known carriers. It should be selected with regard to the intended use of the immobilized polypeptide as a diagnostic antigen or as an immunizing component in a vaccine.

    Examples of carriers that can be used for e.g. diagnostic purposes are magnetic beads or latex of co-polymers such as styrene-divinyl benzene, hydroxylated styrene-divinyl benzene, polystyrene, carboxylated polystyrene, beads of carbon black, non-activated or polystyrene or polyvinyl chloride activated glass, epoxy-activated porous magnetic glass, gelatine or polysaccharide particles or other protein particles, red blood cells, mono or polyclonal antibodies or fab fragments of such antibodies.

    According to a further embodiment of the present invention, the antigens may form part of a vaccine possibly combined with carriers, adjuvants or combined with other immunostimulating elements such as canarypox virus carrying the env gene. Examples of carriers and/or adjuvants for vaccine purposes are other proteins such as human or bovine serum albumin and keyhole limpet haemocyanin and fatty acids. Immunostimulatory materials may be divided into three groups; adjuvants, carriers for antigens and vehicles. Examples of adjuvants include aluminum hydroxyd, aluminum salts, saponin, muramyl di and tripeptides, monophosphoryl lipid A, palmitic acid, B.pertussis and various cytokines including the Th1 cytokine IL-12 and IL-1. A number of protein toxins can be used to carry passenger proteins across cellular membranes into the cytosol, which are useful in developing CTL vaccines. Carriers include bacterial toxoids such as inactivated tetanus and cholera toxins, genetically detoxified bacterial toxins such as heat labile enterotoxin from E. coli, fatty acids, live vectors such as polio chimeras and hybrid proteins that form particulates for example yeast retrotransposon hybrid TY particles and HBcAg particles. Vehicles which are frequently occurring components in modern vaccines are consisting of mineral oil emulsion, Freunds complete and incomplete adjuvant, vegetable oil emulsions, nonionic block co-polymer surfactants, squalene or squalane, lipopeptides, liposomes and biodegradable microspheres. Two recent adjuvants which possess significant potential for the development of new vaccines include an oil-in- water microemulsion (MF59) and polymeric microparticles. Any substance that can enhance the immunogenicity of the antigen may be used and several further alternatives of carriers or adjuvants are given in the US or European Pharmacopoeia.

    A suitable formulation of the antigen for immunostimulatory uses may also comprise interferons such as INF-γ, antiviral chemokines or haematopoietic growth factors such as granulocyte macrophage growth (colony stimulating) factor.

    Another approach in order to enhance the stimulation and absorption in for instance the intestine is to administer the peptides of the invention, with small peptides such as di, tri or tetrapeptides. These peptides can be administered in addition to or in combination with the peptides of the invention. Preferably the peptides are administered together with the tripeptide YGG, consisting of amino acids in the D- or L-forms, preferably in the D-form.

    Recent approaches to non-parenteral delivery of vaccines, for instance via mucosa include; gene fusion technology to create non-toxic derivatives of mucosal adjuvants, genetically inactivated antigens with a deletion in an essential gene, co-expression of an antigen and a specific cytokine that is important in the modulation and control of a mucosal immune response, and genetic material itself that would allow DNA or RNA uptake and its endogenous expression in the host cells.

    One approach for developing durable responses where cell-mediated immunity is required, is to vaccinate with plasmid DNA encoding one or more specific antigen(s).

    In order to protect against HIV infection, vaccines should induce both mucosal and systemic immune responses and could be administered by any convenient route, parenterally or non-parenterally, such as subcutanously, intracutanously, intravenously, intramuscularly, perorally, mucosally or intranasally for example.

    In a preferred embodiment of the vaccine according to the present invention it comprises antigens containing at least one of the peptides selected from the groups of SEQ ID NO: 1, 4, 9 and 15, more preferred different peptides occur in equal amounts.

    In a further preferred embodiment the vaccine composition contains the antigens;
    R L I Y A T R Q L Q R F A V N P G L L I T-NH2 (SEQ ID NO: 3)  
     
    F I L Q N I E G Q L V G G G Y A I S P R T L V A G G G G (SEQ ID NO: 6)
     
    Y A I P Q A L N T L L N T V G G H Q A A-NH2 (SEQ ID NO: 11)
    and
     
    W S A L A G T T S L L Q G Q L G W I T-NH2 (SEQ ID NO: 14)

    The sequences contribute with CTL-epitopes and can activate the cellular immune system. The amino acid changes implemented within the frame of the CTL-epitopes are designed to achieve enhanced binding. Other amino acid changes have been conducted in order to facilitate the synthesis of the peptide and/or to increase the solubility of the peptide.

    A method for detecting antibodies, induced by HIV-1 or HIV-1 specific peptides or proteins, in a sample of body fluid using the present antigens is a further embodiment of the invention. Also immunoassay kit designed for this detection and antibodies capable of selectively reacting with the said antigens are encompassed by the present invention.

    Description of the Preparation of the Peptides

    The peptides of the invention can be produced by any known method of producing a linear amino acid sequence, such as recombinant DNA techniques. A nucleic acid sequence which encodes a peptide of the invention or a multimer of the said peptides, is introduced into an expression vector. Suitable expression vectors are for instance plasmids, cosmids, viruses and YAC (yeast artificial chromosome) which comprise necessary control regions for replication and expression. The expression vector may be stimulated to expression in a host cell. Suitable host cells are for example bacteria, yeast cells and mammalian cells. Such techniques are well known in the art and described for instance by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989. Other well-known techniques are degradation or synthesis by coupling of one amino acid residue to the next one in liquid phase or preferably on a solid phase (resin) for instance by the so-called Merrifield synthesis. See for instance Barany and Merrifield in the Peptides, Analysis, Synthesis, Biology, Vol. 2, E. Gross and Meinhofer, Ed. (Acad. Press, N.Y., 1980), Kneib-Coronier and Mullen Int. J. Peptide Protein Res. 30, p. 705-739 (1987) and Fields and Noble Int.J.Peptide Protein Res., 35, p. 161-214 (1990).

    In case a linked or cyclic peptide is desired, the amino acid sequence is subjected to a chemical oxidation step in order to cyclize or link the two cysteine residues between two peptide sequences, when the appropriate linear amino acid sequences are synthesized, see Akaji et al., Tetrahedron Letter, 33, 8, p. 1073-1076, 1992.

    General Description of Synthesis

    All peptide derivatives prepared in the Examples given below were synthesized on a Milligen 9050 Peptide Synthesizer using a standard program. The resin used was Tenta Gel P RAM with a theoretical loading of 0.20 meq/g (RAPP POLYMERE GmbH, Tübingen). The final product of the synthesis was dried in vacuo overnight. The peptide was then cleaved from the resin by treatment with 90% trifluoroacetic acid in the presence of ethane dithiol (5%) and water (5%) as scavengers (1.5 hours at RT). Then the resin was filtered and washed on filter with additional trifluoroacetic acid (100%) (2×20 ml). The combined filtrates were evaporated in vacuo (water bath at RT) and the residue was triturated with ethyl ether (200 ml) and the precipitated product filtered off. The solid was promptly dissolved on filter with glacial acetic acid (100 ml) and added to 1.5 l of 20% acetic acid in methanol and treated with 0.1 M solution of iodine in methanol until a faint brown colour remained. Then Dowex 1×8 ion exchange in acetate form (15 g) (Bio-Rad, Richmond, Calif.) was added and the mixture filtered. The filtrate was evaporated and the residue freeze-dried from acetic acid. The product was then purified by reversed phase liquid chromatography on a column filled with Kromasil® 100-5 C8 (EKA Nobel, Surte, Sweden) in a suitable system containing acetonitrile in 0.1% trifluoroacetic acid water solution. The samples collected from the column were analyzed by analytical high performance liquid chromatography (HPLC) (Beckman System Gold, USA) equipped with a Kromasil® 100-5 C8 Column (EKA Nobel, Surte, Sweden). Fractions containing pure substance were pooled, the solvent was evaporated and the product freeze-dried from acetic acid. The final HPLC analysis was performed on final product, and the structure of the peptide was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

    All amino acids used during the synthesis were L-amino acids and they were protected with a fluorenylmethoxy-carbonyl group at the α-amino function. The side chains were protected as follows:

  • Cys (Trt), Gln(Trt), Glu(OtBu), Thr(tBu).

    The abbreviations, within the brackets are:
  • Trt=triphenylmethyl
  • t-Bu=tert. Butyl
  • OtBu=tert. Butylester

    The amino acid derivatives was supplied by Bachem AG, Switzerland.
     
  • Claim 1 of 7 Claims

    1. An isolated HIV-1 gag p17 peptide comprising the amino acid sequence of SEQ ID NO: 3, wherein the terminal ends of the sequence may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof and/or the sequence is immobilized to a solid support.

    ____________________________________________
    If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

     

     

         
    [ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
    [ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

    [ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
    [ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
    [ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
    [ Site Map ]